End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
22,250 KRW | -0.45% | +0.45% | -2.84% |
Mar. 14 | Seegene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 24 | Seegene Inc. Announces Collaboration with Microsoft to Realize a World Free from All Diseases | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- With an expected P/E ratio at 67.42 and 24.76 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.84% | 750M | C+ | ||
-26.80% | 9.96B | A- | ||
+65.44% | 3.76B | D+ | ||
-28.13% | 2.37B | C | ||
-10.06% | 2.27B | - | B- | |
-25.01% | 1.58B | C+ | ||
+50.53% | 1.31B | B- | ||
-7.83% | 575M | C- | ||
-27.35% | 525M | C- | ||
+14.12% | 337M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- A096530 Stock
- Ratings Seegene, Inc.